Find Academic Supervisors

• Parasitology
• Infectious Diseases
• Antimicrobial Agents
• +4 more

Anasuya Pal is an Associate Research Scientist in the Department of Infectious Diseases at Yale School of Medicine. Her research focuses on parasitic infections such as Babesia and Plasmodium species, with a strong emphasis on developing diagnostic tools, antiparasitic therapies, and understanding parasite biology. She holds a PhD in Microbiology and Cell Biology from the Indian Institute of Science, along with advanced degrees from the University of Calcutta. Education: PhD, Microbiology and Cell Biology, Indian Institute of Science (20??) MS, Biochemistry, University of Calcutta (1995) BS, Chemistry (Hons.), University of Calcutta (1993) Her research interests include: Mechanisms of parasite-host interactions in Babesia and Plasmodium Development of novel antiparasitic drugs targeting metabolic pathways Design of diagnostic assays for tick-borne pathogens Investigation of cytochrome bc1 complex as a drug target Recent work has explored: Kalihinol analogs disrupting apicoplast function in malaria parasites Tafenoquine-atovaquone combination therapies for babesiosis Pantothenate kinase as a target for antifungal development Collaborations include work with Choukri Ben Mamoun, Pallavi Singh, and Albert Ko, among others. Her lab contributes to both basic science and translational research in infectious diseases.

Bahez GarebView profile

Assistant Professor

• Pharmaceutical Science
• Pharmacology
• Biotechnology
• +5 more

Dr. Bahez Gareb serves as an Assistant Professor at the Faculty of Medical Sciences, University of Groningen, and works as a Hospital Pharmacist at the University Medical Center Groningen (UMCG). His contact information includes telephone +31 50 361 7870 and email b.gareb01@umcg.nl. He maintains dual roles bridging academic research with clinical pharmacy practice, with particular focus on advanced therapy medicinal products and pharmaceutical compounding. Dr. Gareb's research expertise spans pharmaceutical science, biotechnology, and advanced therapy medicinal products (ATMPs), with special emphasis on chimeric antigen receptor (CAR) T cells, pharmaceutical compounding, and good manufacturing practices. His fingerprint analysis reveals significant contributions to Hospital Pharmacy (100%), Good Manufacturing Practice (47%), and inflammatory bowel disease treatment. His work directly addresses United Nations Sustainable Development Goals related to good health and well-being through innovations in drug development and quality control systems. His publication record shows consistent output with 18 research items including 12 articles, 2 book chapters, and other academic contributions. Recent work focuses on CAR-T cell quality control, clinical-grade cell therapy production, and targeted drug delivery systems. The trend indicates increasing specialization in advanced therapy medicinal products and point-of-care manufacturing approaches. Dr. Gareb actively contributes to professional development through multiple leadership roles: Member of the Cellular Therapy Facility Board at UMCG Member of NVZA Commission for Aseptic Handlings and Microbiology Board member of Dutch Immune Effector Cell working group (HOVON) Participant in Dutch ATMP working group Member of DARE-NL Member of training team for hospital pharmacists in training His academic service includes serving on PhD examination committees, guest editing for Pharmaceutics journal, and delivering invited presentations on CAR-T cell manufacturing. Media coverage of his work includes both professional research reporting and popular science articles about hospital cost savings through optimized pharmaceutical practices.

Thomas TolbertView profile

Associate Professor

• Protein Therapeutics
• Glycosylation Effects
• Biopharmaceuticals
• +3 more

Thomas J. Tolbert is an Associate Professor in the Department of Pharmaceutical Chemistry at the University of Kansas School of Pharmacy. His research focuses on the effects of glycosylation on protein therapeutics and site-selective protein modification, particularly in antibody engineering and antibody-drug conjugates. He holds a B.S. in Chemistry from Purdue University, a Ph.D. in Biochemistry from MIT, and completed postdoctoral research at the Scripps Research Institute. Research Interests: Dr. Tolbert’s work addresses glycosylation’s impact on antibody stability and function, development of homogeneous glycoforms for biosimilar analysis, and site-specific conjugation techniques for targeted drug delivery. His lab uses enzymatic synthesis, mass spectrometry, and biophysical methods to study protein glycosylation dynamics and design next-generation biopharmaceuticals. Key Projects: Includes studies on IgG subclasses (IgG1, IgG2, IgG4), Fc receptor interactions, and photochemical degradation mechanisms. His team develops chimeric molecules like Fc-BPI fusions for autoimmune therapies and investigates glycan microheterogeneity in biosimilarity assessments. Laboratory: Based in Simons Biosciences Research Laboratories (Room 201C), his group integrates chemical synthesis, protein engineering, and analytical chemistry to advance therapeutic protein design.

Shannon P. Fortin EnsignView profile

Assistant Professor

• Neuro-Oncology
• Glioma Biology
• Cancer Genomics
• +3 more

Dr. Shannon P. Fortin Ensign is an Assistant Professor of Medicine at Mayo Clinic, specializing in Neuro-Oncology. She holds dual appointments as a Senior Associate Consultant in the Division of Hematology/Oncology (Department of Internal Medicine) and Cancer Biology (Department of Research). Her research focuses on glioma genomics, molecular mechanisms of treatment resistance, and translational therapies for brain tumors. She leads a translational lab studying glioma biology and participates in clinical trials to advance targeted treatments. Education: MD/PhD from University of Arizona/Translational Genomics Research Institute Residency: Internal Medicine at Scripps Green Hospital Fellowship: Hematology/Oncology at Mayo Clinic Arizona Her research interests include cancer genomics, intratumoral heterogeneity, and identifying therapeutic vulnerabilities in gliomas. She has pioneered studies on EGFRvIII-driven glioblastoma resistance and molecular imaging biomarkers for meningioma. Her work bridges clinical care and research, aiming to improve patient outcomes through precision medicine. Dr. Fortin Ensign has published extensively on glioma biology, neuro-oncology therapies, and clinical trials. Notable publications include work on EGFRvIII drug sensitivity (2024) and integrated molecular mapping of gliomas (2023). Awards include the Mayo Brothers Distinguished Fellowship Award (2022) and National Goldwater Scholarship (2006). Awards: Over 20 honors, including Phi Mu Foundation grants and Society for Neuro-Oncology recognitions Professional Roles: Track Chair for CNS Rare Tumors (Society for Neuro-Oncology) She oversees clinical trials for brain tumors and advises on translational research strategies. Her lab collaborates with Mayo’s Comprehensive Cancer Center and Advanced Clinical Trials program to advance neuro-oncology therapies.

• Neuroscience
• Molecular Neurobiology
• Potassium Channels
• +4 more

Sönke Hornig is a researcher at the University Medical Center Hamburg-Eppendorf, specifically affiliated with the Center for Molecular Neurobiology Hamburg (ZMNH) under the Hamburg Center of Neuroscience. He has been actively publishing research from 2006 through 2024, demonstrating ongoing contributions to neuroscience and molecular biology. His research primarily focuses on molecular neurobiology with emphasis on: Potassium channel structure, function, and pharmacology Creatine and guanidino compound metabolism Cerebellar function and Purkinje cell physiology Neurodegenerative processes and neuroprotection Stroke and cerebrovascular disease mechanisms Hornig's work spans multiple disciplines including neuroscience, biochemistry, biophysics, and clinical research. His research approach combines molecular techniques, electrophysiology, mouse models, and clinical studies to investigate fundamental neurobiological processes and their implications for human disease. His recent publications show a continued focus on potassium channels, cerebellar function, and the role of guanidino compounds in neurological and vascular conditions. Hornig has collaborated extensively with researchers at the University Medical Center Hamburg-Eppendorf, particularly with the group led by Prof. Choe (Chiun Choe), with whom he has co-authored numerous papers on creatine metabolism and guanidino compounds.

Joseph M. LunaView profile

Assistant Professor

• RNA Biology
• Molecular Virology
• Host-Pathogen Interactions
• +4 more

Joseph M. Luna, PhD is an Assistant Professor in the Department of Biochemistry at Case Western Reserve University's School of Medicine. He leads the Luna Lab, which focuses on RNA-binding proteins (RBPs) in viral infections and cellular stress responses. His work uses positive-sense RNA viruses as models to study viral replication, innate immunity, and host-pathogen interactions. Member of the Center for RNA Science and Therapeutics Member of the Cancer Genomics and Epigenomics Program at Case Comprehensive Cancer Center Director of the Advanced RNA Profiling Core PhD from The Rockefeller University (2015) Postdoctoral training at The Rockefeller University Research interests include: - Subcellular RBP:RNA interaction mapping using novel spatial CLIP techniques - Dynamics of RBPs during viral infections (HCV/SARS-CoV-2) - RBP networks in innate immunity - Development of advanced RNA-profiling methods Recent work emphasizes: - Spatial resolution of RNA interactions in viral replication organelles - CRISPR-based screening for host factors in coronavirus infections - Systems-level modeling of RBP activities Key achievements include: - Co-developed SARS-CoV-2 replicon systems enabling antiviral research - Identified miR-122 sequestration mechanisms in hepatitis C infection - Trained students from underrepresented groups in biomedical research Labs/Teams: - Advanced RNA Profiling Core facility director - Collaborations with virology, immunology, and systems biology groups

• mRNA Vaccine Development
• Viral-Vectored Vaccines
• Arbovirus Vaccinology
• +5 more

Dr. Cesar Lopez-Camacho serves as a Group Leader and Jenner Investigator at the University of Oxford's Nuffield Department of Medicine within the Medical Sciences Division. Leading the RNA Technology Programme at the Jenner Institute, he directs research on mRNA vaccine platforms and arthropod-borne pathogen vaccines. His team comprises two postdoctoral scientists and two DPhil students developing novel Lipid Nanoparticle delivery systems. His research spans mRNA vaccine development , viral-vectored vaccines , and arbovirus immunopathogenesis . Specializing in Dengue, Zika, Chikungunya, and malaria vaccines, his work integrates molecular cloning, in-silico gene design, and immune response analysis. During the pandemic, he engineered SARS-CoV-2 antigens for diagnostics and immune monitoring while serving on the UK Parliament's COVID-19 Expert Database and National Testing Scientific Advisory Panel. Analysis of his 15 most recent publications reveals dominant focus on coronavirus variant immune evasion (70% of 2020-2021 work), malaria vaccine platforms (2024 lead publication), and cross-protective alphavirus immunity . His research consistently bridges structural virology with translational vaccinology, emphasizing pre-clinical validation in murine models. Ohtli Award from Mexican Government (2021) JFF Grant for mRNA Platform Development NIHR Capital Fund for mRNA Core Facility Dr. Lopez-Camacho advises DPhil students in the Jenner Institute's graduate program while managing multiple grants including the JFF award and NIHR funding. His team operates the newly established mRNA core facility supporting internal and external pre-clinical research. Current projects include combination arbovirus vaccines and next-generation LNP formulations for enhanced immunogenicity.

Nikolaos SgourakisView profile

Professor

• Structural Biology
• Immunology
• Cancer Immunotherapy
• +7 more

Nikolaos Sgourakis is a Professor in the Department of Biochemistry and Biophysics at the Perelman School of Medicine, University of Pennsylvania, with additional affiliations at the Children’s Hospital of Philadelphia (CHOP). His research integrates structural biology, protein engineering, and computational approaches to advance cancer immunotherapy, particularly through understanding the MHC-I antigen presentation pathway. Graduate Group Affiliations: Cell and Molecular Biology, Biochemistry and Molecular Biophysics, Immunology, Pharmacology His research focuses on the structural mechanisms of MHC-I molecules and their role in immune surveillance, with applications in targeting intracellular oncoproteins in pediatric cancers. He develops engineered chaperones and stabilized MHC-I systems to enhance peptide exchange and immunogenicity in 'cold' tumors like neuroblastoma. The most recent publications highlight a strong trend in structural immunology, particularly in understanding antigen presentation, T cell receptor recognition, and engineering novel immunotherapies such as peptide-centric CARs and bispecific T cell engagers. His work frequently employs cryo-EM, computational modeling, and protein design to tackle challenges in personalized cancer therapy. Selected for Cancer Grand Challenges consortium (2022) Selected for Cancer Grand Challenges consortium (2025) Dr. Sgourakis' lab is supported by major collaborative grants through the Cancer Grand Challenges program, enabling international, interdisciplinary research aimed at developing next-generation T cell-based therapeutics. His lab trains graduate students and postdoctoral researchers through affiliations with multiple graduate groups. He has developed molecular tools that are advancing high-throughput T cell screening and antigen discovery. His lab operates at CHOP and is part of a larger collaborative ecosystem at the Penn Autoimmunity Center of Excellence and the Cancer Immunology program. The Sgourakis Lab leverages structural insights to engineer solutions for immune evasion in cancer, positioning it at the forefront of translational immunology.

Terry C. HazenView profile

Professor

• Microbial Ecology
• Environmental Engineering
• Bioremediation
• +12 more

Dr. Terry C. Hazen is the UT/ORNL Governor's Chair Professor in the Department of Civil & Environmental Engineering at the University of Tennessee, Knoxville , with additional appointments in Microbiology, Earth and Planetary Sciences, Genome Science and Technology, and the Bredesen Center. He leads the Hazen Lab, a multidisciplinary research group focused on microbial ecology and environmental engineering. Education: Bachelor of Science (Biology), Michigan State University, 1973 Master of Science (Biology, Parasitology), Michigan State University, 1974 Ph.D. (Parasitology-Ecology, Microbiology-Immunology), Wake Forest University, 1978 His research centers on microbial ecology , particularly in the context of bioremediation , biofuels , enhanced oil recovery , and water quality . He investigates systems biology and environmental stress responses from the molecular to ecosystem level. His recent work explores groundwater microbial communities , nitrous oxide emissions , denitrification , and microbial genomics for nuclear nonproliferation monitoring . The most recent publications highlight advanced work in reactive transport modeling , microbial community assembly , enrichment cultures , and dissolved organic matter analysis using machine learning. These studies are largely conducted at the ENIGMA Field Research Center at Oak Ridge, focusing on contaminated subsurface environments. Scientific Awards and Recognition: ASM Award for Environmental Research (2021) UT/ORNL Governor's Chair Professor Seaborg Fellow Chancellor’s Fellowship (advised student) NSF Fellowship (advised postdoc) Dr. Hazen has advised numerous Ph.D. and M.S. students and mentored many postdoctoral fellows and research associates. His lab has received significant recognition, with several members listed among the Stanford World’s Top 2% Cited Scientists . He has been actively involved in national and international responses to oil spills , including the Deepwater Horizon and Peru Repsol incidents. His lab holds multiple patents in bioremediation technologies and maintains strong collaborations with Oak Ridge National Laboratory . Laboratories and Facilities: The Hazen Lab operates at both the University of Tennessee (SERF and Tickle Engineering Building) and Oak Ridge National Laboratory (JIBS), utilizing state-of-the-art equipment for microbial and environmental research.

Maura Dandri-PetersenView profile

Research Professor

• Viral hepatitis
• Hepatitis B virus
• Hepatitis D virus
• +6 more

Maura Dandri-Petersen is a Research Professor holding a Heisenberg-Professorship for Viral Hepatitis at the I. Department of Medicine, Center for Internal Medicine, University Medical Center Hamburg-Eppendorf (UKE). She maintains an active research program focused on viral hepatitis pathogenesis and therapeutics, particularly hepatitis B and D viruses. Her primary research interests include viral hepatitis mechanisms, hepatitis B virus (HBV) and hepatitis D virus (HDV) pathogenesis, cccDNA dynamics, viral replication, and antiviral therapy development. She has pioneered research using human liver-chimeric mouse models to study hepatitis virus infections and evaluate novel therapeutic approaches. Analysis of her recent publications shows a strong focus on HDV treatment with bulevirtide, cccDNA quantification methods, viral-host interactions, and immune responses during hepatitis virus infections. Her work bridges basic virology with clinical applications, contributing significantly to the understanding of viral persistence and therapeutic interventions. Scientific Awards: EMBO-Long-term Postdoc-Fellowship at Heinrich-Pette-Institut, Universität Hamburg (1999-2000) Deutsche Krebshilfe Scholarship (1998) W3-Heisenberg-Professorship (DFG) in Virushepatitis Her research has been instrumental in developing and validating humanized mouse models for hepatitis virus research, contributing to numerous clinical trials and therapeutic approaches for viral hepatitis. She has extensive experience with molecular virology techniques, viral quantification methods, and translational research from bench to bedside.

Lydia UshaView profile

Professor

• Cancer Genetics
• Inherited Cancer Syndromes
• Breast Cancer
• +7 more

Lydia Usha, MD is a Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College, Rush University . She serves as the Director of the Rush Inherited Susceptibility to Cancer (RISC) Center, highlighting her leadership in cancer genetics and hereditary cancer risk assessment. Her clinical and research work is centered at the RUSH MD Anderson Cancer Center, with practice locations in Chicago and Oak Park, IL. Research Interests: Dr. Usha specializes in cancer genetics , particularly inherited cancer syndromes such as those involving PALB2 and BRCA genes, breast and ovarian cancer , and molecular oncology . Her work bridges clinical oncology with genetic research, focusing on risk assessment, tumor genomics, and treatment complications. Publication Trends: Her recent publications (2018–2023) reflect a strong focus on hereditary cancer risk , genetic phenocopies , imaging guidelines for survivors , and adverse effects of targeted therapies . She frequently contributes to high-impact journals and participates in international collaborative studies. Scientific Contributions: Key contributor to international studies on PALB2 gene variants and cancer risk. Published on rare complications of breast cancer therapy, including autoimmune hepatitis and folate deficiency. Explored innovative topics such as chimerism in cancer families and radiosensitization with anti-HER2 agents. Clinical and Academic Leadership: Dr. Usha is actively involved in both patient care and academic research, embodying the mission of an academic medical center. Her role as Director of the RISC Center underscores her commitment to identifying and managing patients with inherited cancer susceptibility. She collaborates widely and publishes in oncology, genetics, and radiology journals, demonstrating interdisciplinary impact. Laboratory and Team Affiliations: She is affiliated with the Rush Inherited Susceptibility to Cancer (RISC) Center , where she leads research and clinical programs focused on genetic cancer risk. Her work involves multidisciplinary teams integrating clinical oncology, genetics, and molecular biology.

Shadi Farzin GoharView profile

Assistant Professor

• Pediatric Hematology
• Oncology
• Leukemia
• +3 more

Shadi Farzin Gohar, MD is an Assistant Professor at Loma Linda University School of Medicine within the Pediatric Hematology and Oncology Division . They actively contribute to pediatric cancer research, focusing on CRLF2 signaling in Ph-like ALL , cytokine therapies , and health disparities in Hispanic leukemia patients . Research interests include: Elucidating mechanisms of TSLP and CRLF2 in B-ALL pathogenesis Developing patient-derived xenograft models for preclinical testing Improving targeted therapies and signal transduction strategies Addressing health disparities in pediatric oncology Recent publications highlight work on cytokine therapy (TSLP), CRLF2 receptor targeting, and signal shutdown mechanisms in leukemia. Clinical trials led by Dr. Gohar span COG protocols for rhabdomyosarcoma , neuroblastoma , and hematopoietic cell transplantation , supported by organizations like the National Cancer Institute and Children's Oncology Group .

• Vaccinology
• Immunology
• Infectious Diseases
• +12 more

Dr. Ahmed M. Salman is a Senior Immunologist-Vaccinologist and Research Group Leader at the Jenner Institute, University of Oxford, and a Fellow at Kellogg College. He leads research in innovative vaccine development against infectious diseases such as malaria and COVID-19, and also contributes to gene therapy for retinal disorders. He works in collaboration with the Pirbright Institute and Leiden University Medical Centre, and is a Co-PI on projects funded by the Bill & Melinda Gates Foundation, European Commission, and MRC. Education: BSc in Biochemistry, Ain Shams University, Egypt (2006) MSc in Tuberculosis Immunology, Ain Shams University in collaboration with Statens Serum Institut, Denmark (2011) DPhil (PhD) in Clinical Medicine, University of Oxford (awarded 2015) Dr. Salman’s research focuses on identifying and assessing novel vaccine antigens using advanced technologies in immunology, molecular biology, and bioinformatics. His work spans viral vector vaccines, VLP platforms, and gene editing tools like CRISPR/Cas. He has made significant contributions to antigen down-selection for clinical trials, including the Oxford-AstraZeneca COVID-19 vaccine and next-generation malaria vaccines targeting both P. falciparum and P. vivax. His recent publications reveal a dual focus: (1) vaccine immunology and development, particularly in malaria and pandemic response, and (2) cutting-edge gene therapy approaches for retinal diseases. This interdisciplinary trend highlights his expertise across vaccinology and regenerative medicine. Additionally, he has published on AI applications in cybersecurity education, indicating broad scientific engagement. Scientific Awards and Recognition: Named inventor on three Plasmodium falciparum malaria vaccine patents Recipient of EVIMalaR PhD scholarship funded by the European Commission and EMBL Dr. Salman advises and leads a research group within the Jenner Institute’s Pre-erythrocytic Vaccines Programme. He has secured and contributed to major grants from global funders including the Bill & Melinda Gates Foundation and Medical Research Council. His leadership in clinical trial-related antigen selection has had significant real-world impact. He is a member of the British Society for Immunology (BSI), American Society of Tropical Medicine and Hygiene (ASTMH), and the International Veterinary Vaccinology Network (IVVN). His work is conducted within state-of-the-art facilities including the Jenner’s VLP and Insectary (SRF) units, which he manages, supporting vaccine production and preclinical testing.

Jeffrey R MorganView profile

Professor

• 3D Cell Culture
• Tissue Engineering
• Biomedical Engineering
• +7 more

Jeffrey R Morgan is a tenured Professor at Brown University , holding dual appointments in the School of Engineering and Department of Pathology and Laboratory Medicine . He directs the Center for Alternatives to Animals in Testing and has pioneered the 3D PetriDish® technology for scaffold-free tissue engineering. Education : PhD (Harvard), BS (Syracuse) Key Collaborators : Kim Boekelheide, Eric Darling, Anubhav Tripathi Research Focus : 3D Tissue Engineering – Developing complex microtissue geometries (toroids, honeycombs) and studying tissue fusion for organ-scale fabrication. Cell-Cell Mechanics – Quantifying forces in multicellular aggregates to understand fibrosis and tissue remodeling. Drug Transport – Using spheroids to model drug uptake, efflux pumps, and multi-drug resistance in cancer. Article Trends : Recent work emphasizes 3D spheroid platforms for toxicity testing , collagen mechanics , and automated bio-manufacturing tools . Keywords span Biomedical Engineering , Tissue Morphogenesis , and Drug Discovery , with sub-fields including ECM alignment , microtissue hydrodynamics , and scaffold-free organoids . Scientific Recognition : 1996 La Roche-Posay Prize 2015 National Academy of Inventors Fellow 2016 American Institute of Medical and Biological Engineering Fellow 2014-2025 Editorial roles and collaborative grants Labs and Teams : Leads a multidisciplinary lab at Brown collaborating with engineers, pathologists, and biomedical researchers. His team focuses on self-assembling microtissues , drug transport quantification , and toxicity modeling , with partnerships in the Center for Alternatives to Animals in Testing and School of Engineering .

Li GanView profile

Professor

• Neurodegeneration
• Alzheimer's disease
• Tauopathies
• +6 more

Li Gan, Ph.D., is the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases at the Brain and Mind Research Institute, Weill Cornell Medical College. Since 2018 she has led an interdisciplinary program that integrates human iPSC-based disease modeling, single-cell multi-omics, and therapeutic target discovery to combat Alzheimer’s disease and related tauopathies. Education Ph.D., Yale University School of Medicine (1996) B.S., Peking University, China (1990) Research Focus Dr. Gan’s laboratory investigates how microglial innate immunity, tau post-translational modifications, and sex-specific pathways drive neurodegeneration. Using CRISPR-engineered human induced pluripotent stem cell (iPSC) models, brain organoids, and chimeric mouse brains, her team decodes cell-type-specific vulnerabilities and designs first-in-class therapeutics—including cGAS inhibitors, anti-acetyl-tau antibodies, and small-molecule modulators of microglial homeostasis. Grants & Support NIA “Mapping proteomic changes of tauopathy in human neurons” (PI, 2025-2030) Cure Alzheimer’s Fund “Sex-biased TLR7 signaling” (PI, 2025) NIA “Acetylated Tau Immunotherapy” (PI Subaward, 2025-2026) JPB Foundation “Targeting maladaptive innate immune response” (PI, 2024-2027) Rainwater Charitable Foundation series on cGAS inhibitors and 4R tauopathy models (PI, 2024-2025) Chan Zuckerberg Initiative & Ludwig Family Foundation awards for neuro-immune resilience studies Industry & Advisory Roles Dr. Gan serves as Scientific Advisory Board Member for Arvinas, Inc. and Neurovanda Therapeutics; consultant to Aeton Therapeutics, LSG Therapeutics, and NeuroLambda Therapeutics; and maintains equity/proprietary interests in these companies plus Retro Biosciences, reflecting long-standing translational collaborations. Laboratory & Teams The Gan Lab operates within the Brain and Mind Research Institute’s state-of-the-art facilities, hosting post-doctoral fellows, graduate students, and research technicians focused on high-throughput CRISPRi/a screening, single-cell epigenomics, and pre-clinical testing of therapeutic leads. Active partnerships extend to the NIH-funded Alzheimer’s Disease Tau Platform Clinical Trial Network and international open-science consortia.